Perioperative Anaphylaxis: A Potential Hazard to the Safety of Surgical Patients

0
0
0

Perioperative Anaphylaxis: A Potential Hazard to the Safety of Surgical Patients

Perioperative anaphylaxis represents a rare yet severe and potentially life-threatening allergic reaction that poses unique challenges in the context of surgical care. Characterized by multisystem involvement, it manifests through cutaneous, cardiovascular, respiratory, gastrointestinal, and central nervous system symptoms. Despite its low incidence—estimated to range from 1:20,000 to 1:381 during general anesthesia—its delayed recognition and management contribute disproportionately to high mortality rates. This article explores the etiology, clinical presentation, diagnostic challenges, severity grading, and immediate interventions critical to mitigating risks associated with perioperative anaphylaxis.

Etiology and Epidemiology

The primary triggers of perioperative anaphylaxis vary geographically and institutionally, influenced by drug availability, clinical practices, and exposure frequency. Neuromuscular blocking agents (NMBAs), antibiotics, and chlorhexidine are among the most frequently implicated agents.

Neuromuscular Blocking Agents (NMBAs)

NMBAs are the leading cause of perioperative anaphylaxis globally. Significant regional disparities exist in the prevalence of hypersensitivity reactions to specific NMBAs. In the United Kingdom and Western Australia, rocuronium accounts for 41.5% and 71% of NMBA-related anaphylaxis cases, respectively, with incidences of 5.9 and 8.0 per 100,000 administrations. In contrast, succinylcholine dominates in France, responsible for 64% of reactions at a rate of 14.8 per 100,000 administrations. Atracurium and cisatracurium exhibit lower but non-negligible risks, while pancuronium and mivacurium are rarely implicated. These variations highlight the impact of local prescribing patterns and drug preferences on anaphylaxis epidemiology.

Antibiotics

Beta-lactam antibiotics, particularly penicillins and cephalosporins, are increasingly recognized as major triggers. Hypersensitivity reactions may arise from reactivity to the beta-lactam ring or side chains. Perioperative antibiotic administration for surgical prophylaxis has led to a rising proportion of antibiotic-related anaphylaxis, placing these agents among the top three culprits in recent studies.

Chlorhexidine

Chlorhexidine, a widely used antiseptic, has emerged as an underrecognized trigger due to atypical presentations. Exposure routes include cutaneous application (surgical skin preparation), mucosal contact (urethral catheter lubricants), and parenteral administration (chlorhexidine-coated central venous catheters). Alarmingly, only 28% of chlorhexidine-induced reactions are initially suspected by anesthesiologists. Failure to identify and remove the source, such as coated catheters, may result in prolonged or refractory anaphylaxis.

Other Triggers

Additional agents include latex (historically significant but declining due to reduced usage), gelatin-based colloids, and dyes such as patent blue.

Clinical Presentation and Diagnostic Challenges

Perioperative anaphylaxis shares clinical features with anaphylaxis in other settings but presents unique diagnostic hurdles. Under anesthesia, key symptoms may be masked:

  • Cardiovascular: Hypotension (often abrupt) and tachycardia are hallmark signs, progressing to circulatory collapse if untreated. Sympathetic blockade from anesthetics can exacerbate hypotension.
  • Respiratory: Bronchospasm, oxygen desaturation, elevated airway pressures, and angioedema complicate ventilation.
  • Cutaneous: Erythema, urticaria, or angioedema occur in 80% of cases but may be concealed by surgical drapes.
  • Gastrointestinal/Central Nervous Systems: Symptoms like abdominal pain, vomiting, confusion, or loss of consciousness are detectable only in conscious patients.

Diagnostic Criteria

Diagnosis requires two elements:

  1. Acute Onset: Most reactions occur within minutes of intravenous trigger exposure. Delayed presentations (>15 minutes) may follow subcutaneous, mucosal, or peritoneal exposure (e.g., latex, chlorhexidine).
  2. Multisystem Involvement: At least two organ systems must exhibit signs. Notably, cutaneous symptoms may be absent in 20% of cases, necessitating vigilance for cardiovascular or respiratory abnormalities.

Severity Grading Systems

Stratifying severity guides management and facilitates research. Three systems are widely referenced:

Ring and Messmer Scale

This four-tier classification aligns with clinical urgency:

  • Grade 1 (Mild): Cutaneous signs only (erythema, urticaria).
  • Grade 2 (Moderate): Cutaneous, cardiovascular (hypotension, tachycardia), and respiratory (cough, bronchospasm) involvement.
  • Grade 3 (Severe): Life-threatening manifestations (cardiovascular collapse, arrhythmias, severe bronchospasm) requiring aggressive intervention.
  • Grade 4 (Arrest): Cardiac or respiratory arrest.

Scandinavian Guidelines

Expanding the above, this system adds Grade 5 (Death) to account for fatalities despite resuscitation.

Perioperative Anaphylaxis Grading System (PAGS)

Developed by the Australian and New Zealand Anesthetic Allergy Group, PAGS simplifies categorization:

  • Grade A (Moderate): Non-life-threatening multisystem involvement.
  • Grade B (Life-Threatening): Severe cardiovascular or respiratory compromise.
  • Grade C (Cardiac/Respiratory Arrest): Requires advanced life support.

PAGS omits mild reactions (Grade 1) as isolated cutaneous symptoms do not mandate epinephrine or resuscitation.

Immediate Management

Prompt administration of intravenous epinephrine and fluid resuscitation forms the cornerstone of treatment. Delayed epinephrine correlates with increased mortality, yet dosing must balance efficacy against risks of arrhythmias or hypertensive crises.

Epinephrine Dosing Strategies

Guidelines vary by region (Table 2):

  • Grade 2 Reactions: Initial bolus doses range from 10–50 µg (Europe) to 20–30 µg (Australia/New Zealand). Escalating doses (50–200 µg) are advised for refractory hypotension.
  • Grade 3/4 Reactions: Boluses of 100–200 µg or infusions (0.05–0.1 µg/kg/min) are recommended. Cardiac arrest warrants 1 mg boluses per advanced life support protocols.

Fluid Resuscitation

Crystalloids (0.9% saline, Ringer’s lactate) are prioritized, with rapid administration of 500–2000 mL initially and up to 30 mL/kg in severe cases. Colloids may substitute if crystalloids fail to restore perfusion.

Adjunctive Measures

  • Positioning: Elevating the lower limbs enhances venous return.
  • Airway Management: Secure patency in angioedema or bronchospasm; consider nebulized bronchodilators.
  • Trigger Removal: Discontinue suspected agents (e.g., stop chlorhexidine-coated catheter use).

Prevention and Awareness

Prophylactic strategies include:

  • Preoperative Allergy Screening: Detailed history-taking to identify prior reactions to NMBAs, antibiotics, or latex.
  • Avoidance of High-Risk Agents: Substituting rocuronium with low-risk NMBAs (e.g., cisatracurium) in sensitized patients.
  • Education: Training anesthesiologists to recognize atypical presentations (e.g., isolated hypotension) and adhere to treatment algorithms.

Conclusion

Perioperative anaphylaxis remains a formidable challenge due to its variable presentation, diagnostic complexity, and rapid progression. Heightened clinical suspicion, familiarity with severity grading, and adherence to epinephrine-based resuscitation protocols are essential to improving outcomes. Regional variations in causative agents underscore the need for tailored preventive approaches. Future research should focus on standardized diagnostic criteria, optimized treatment algorithms, and enhanced surveillance systems to reduce morbidity and mortality.

doi.org/10.1097/CM9.0000000000000659

Was this helpful?

0 / 0